Precision Medicine

A new telehealth platform offers prescription-only CBD, navigating a major regulatory shift that will reshape the entire cannabis industry. Here's what's next.

By partnering with BioBrasil to produce key diagnostic probes locally, Aliko Scientific is not just entering a market; it's rewriting the rules of play.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

A breakthrough system grows larger, more complex human gut tissues twice as fast, promising to revolutionize drug testing and regenerative medicine.

Gene Solutions' AI-driven multi-omics liquid biopsy platform makes waves at a major oncology conference, finding a ready market in Taiwan.

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

New data shows Moleculin Biotech's Annamycin avoids heart toxicity, a breakthrough that could transform treatment for leukemia and sarcoma patients.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Central Ohio cancer patients gain unprecedented access to advanced therapies and clinical trials as Zangmeister Cancer Center joins OSU's James Cancer Network.

With new CEO Andrew Zeringue, Theromics aims to tackle cancer recurrence with its HeatSYNC gel, a novel approach in the booming ablation market.

New Callisto protocol for Oxford Nanopore achieves diagnostic-grade accuracy, paving the way for routine whole genome sequencing in clinical settings.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

A new partnership combines AI-driven precision with deep gene therapy expertise, aiming to overcome critical safety hurdles and redefine treatment for rare diseases.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

With a new CCO and advanced T-Body™ platform, Invenra is shifting from R&D to aggressive commercialization. Can it dominate the multispecific antibody market?

With new CMO Anisha Raghavan, the science-heavy supplement brand plans to translate its complex clinical research into mainstream consumer success.

A new collaboration between the digital health giant and a top cancer center aims to deliver expert insights to doctors worldwide, tackling a complex field.